Merck to present new research data across its HIV prevention and treatment pipeline at IAS 2025
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Subscribe To Our Newsletter & Stay Updated